Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(1):62–78. doi: 10.1111/j.1750-3639.2003.tb00007.x

Phosphorylated Protein Kinases Associated with Neuronal and Glial Tau Deposits in Argyrophilic Grain Disease

I Ferrer 1,2,3,✉, M Barrachina 2, M Tolnay 4, MJ Rey 3, N Vidal 1, M Carmona 2, R Blanco 2, B Puig 2
PMCID: PMC8096000  PMID: 12580546

Abstract

Tau phosphorylation was examined in argyrophilic grain disease (AGD) by using the phosphospecific tau antibodies Thr181, Ser202, Ser214, Ser 396 and Ser422, and antibodies to non‐phosphorylated and phosphorylated mitogen‐activated protein kinase (MAPK), extracellular signal‐regulated kinases (ERK), stress‐activated kinase (SAPK), c‐Jun N‐terminal kinase (JNK), p38 kinase (p‐38), α‐calcium/calmodulin‐dependent kinase II (αCaM kinase II), and glycogen synthase kinase‐3 (GSK‐3), all of which regulate phosphorylation at specific sites of tau. This is the first study in which the role of protein kinases in tau phosphorylation has been examined in AGD.

Hyperphosphorylated tau accumulated in grains and pre‐tangles in the hippocampus, dentate gyrus, entorhinal and trans‐entorhinal cortices, and amygdala in all cases. Ballooned neurons in the amygdala, entorhinal, insular and cingulate cortex, and claustrum contained αB‐crystallyn and phosphorylated neurofilament epitopes. Some astrocytes and scattered oligodendrocytes containing coiled bodies were recognized with anti‐tau antibodies. A few tangles were observed in the entorhinal cortex and hippocampus corresponding to Alzheimer's disease (AD) stages I‐III of Braak and Braak. None of the present cases was associated with progressive supranuclear palsy or with α‐synuclein pathology. Two bands of phospho‐tau of 64 and 68 kDa were observed in Western blots of sarkosyl‐insoluble fractions enriched with abnormal filaments in AGD, a pattern that contrasts with the 4‐band pattern obtained in AD.

No modifications in the expression of non‐phosphorylated MEK‐1, ERK2 and GSK‐3α/β, as revealed by immunohistochemistry, were seen in AGD, but sarkosyl‐insoluble fractions were particularly enriched in JNK‐1 and αCaM kinase II. Increased expression of the phosphorylated (P) forms of MAPK/ERK, SAPK/JNK, p38 and GSK‐3β was found in grains and tau‐containing cells in AGD. MAPK/ERK‐P immunoreactivity was observed in pre‐tangles and, diffusely, in the cytoplasm of ballooned neurons, but not in grains. Strong SAPK/JNK‐P and P38‐P, and moderate GSK‐3b‐P immunoreactivities selectively occured in grains, in neurons with pre‐tangles and in the peripheral region of the cytoplasm of ballooned neurons. MAPK/ERK‐P, SAPK/JNK‐P, p38‐P and GSK‐3β‐P were expressed in tau‐containing astrocytes and in oligodendrocytes with coiled bodies. Western blots revealed kinase expression in sarkosyl‐insoluble fractions but none of the phospho‐kinase antibodies recognized hyper‐phosphorylated tau protein.

These findings indicate complex, specific profiles of tau phosphorylation and concomitant activation of precise kinases that have the capacity to phosphorylate tau at specific sites in AGD. These kinases co‐localize abnormal tau in selected structures and cells, including neurons with pre‐tangles, ballooned neurons, astrocytes and oligodendrocytes.

Most of these kinases are involved in cell death and cell survival in certain experimental paradigms. However, double‐labeling studies with the method of in situ end‐labeling of nuclear DNA fragmentation and cleaved (active) caspase‐3 immunohistochemistry show no expression of apoptosis and death markers in cells bearing phosphorylated kinases.

Full Text

The Full Text of this article is available as a PDF (970.9 KB).

References

  • 1. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103: 26–35. [DOI] [PubMed] [Google Scholar]
  • 2. Atzori C, Guetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A (2001) Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60: 1190–11197. [DOI] [PubMed] [Google Scholar]
  • 3. Baudier J, Cole RD (1987) Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin‐dependent kinase and modulated by phospholipids. J Biol Chem 262: 17577–17583. [PubMed] [Google Scholar]
  • 4. Botez G, Probst A, Ipsen S, Tolnay M (1999) Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease. Acta Neuropathol 98: 251–256. [DOI] [PubMed] [Google Scholar]
  • 5. Braak H, Braak E (1987) Argyrophilic grains: Characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 76: 124–127. [DOI] [PubMed] [Google Scholar]
  • 6. Braak H, Braak E (1989) Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 15:13–26. [DOI] [PubMed] [Google Scholar]
  • 7. Braak H, Braak E (1998) Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 105: 801–819. [DOI] [PubMed] [Google Scholar]
  • 8. Braun AP, Schulman H (1995) The multifunctional calcium/calmodulin‐dependent protein kinase: from form to function. Ann Rev Physiol 57: 417–445. [DOI] [PubMed] [Google Scholar]
  • 9. Buée L, Bussière T, Buée‐Scherrer V, Delacourte A, Hof PR (2000) Tau isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33: 95–130. [DOI] [PubMed] [Google Scholar]
  • 10. Buée L, Delacourte A (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP‐17 and Pick's disease. Brain Pathol 9: 681–693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA (1999) Overexpression of 4R‐tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46: 325–332. [DOI] [PubMed] [Google Scholar]
  • 12. Cobb MH, Goldsmith EJ (1995) How MAP kinases are regulated. J Biol Chem 270: 14843–14846. [DOI] [PubMed] [Google Scholar]
  • 13. Cohen P, Frame S (2001)The renaissance of GSK3. Nature Rev 2: 769–776. [DOI] [PubMed] [Google Scholar]
  • 14. Cross D, Culbert A, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death. J Neurochem 77: 94–102. [DOI] [PubMed] [Google Scholar]
  • 15. Crowther RA, Goedert M (2000) Abnormal tau‐containing filaments in neurodegenerative diseases. J Struct Biol 130: 271–279. [DOI] [PubMed] [Google Scholar]
  • 16. Dérijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ (1995) Independent human MAP kinase signal‐transduction pathways defined by MEK and MKK isoforms. Science 267: 682–685. [DOI] [PubMed] [Google Scholar]
  • 17. Drewes G, Lichtenberg‐Kraag B, Doering F, Mandelkow EM, Biernat J, Goris J, Doree M, Mandelkow E (1992) Mito‐gen‐activated protein (MAP) kinase transfoms tau protein into an Alzheimer‐like state. EMBO J 6: 2131–2138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Drewes G, Trinczec B, Illenberger S, Biernat J, Schmitt‐Ulms G, Meyer HE, Mandelkow EM, Mandelkow E (1995) Microtubule‐associated protein/microtubule affinity‐regulating kinase (p110mark). A novel protein kinase that regulates tau‐microtubule interactions and dynamic instability by phosphorylation at the Alzheimer‐specific site serine 262. J Biol Chem 270: 7679–7688. [DOI] [PubMed] [Google Scholar]
  • 19. Enslen H, Raingeaud J, Davis RJ (1998) Selective activation of p38 mitogen‐activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 273: 1741–1748. [DOI] [PubMed] [Google Scholar]
  • 20. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97: 11960–11965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Feany MB, Dickson DW (1996) Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40: 139–148. [DOI] [PubMed] [Google Scholar]
  • 22. Ferrer I, Barrachina M, Puig B (2002) Glycogen synthase kinase‐3 (GSK‐3) is associated with neuronal and glial hyper‐phosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104:583–591. [DOI] [PubMed] [Google Scholar]
  • 23. Ferrer I, Barrachina M, Puig B (2002) Anti‐tau phosphospecific Ser262 antibody recognizes a variety of abnormal hyper‐phosphorylated tau deposits in tauopathies including Pick bodies and argyrophylic grains. Acta Neuropathol 104:658–664. [DOI] [PubMed] [Google Scholar]
  • 24. Ferrer I, Blanco R, Carmona M, Puig B (2001) Phosphorylated mitogen‐activated protein kinase (MAPK/ERK‐P), protein kinase of 38 kDa (p38‐P), stress‐activated protein kinase (SAPK/JNK‐P), and calcium/calmodulin‐dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108: 1397–1415. [DOI] [PubMed] [Google Scholar]
  • 25. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Viñals F, Ribalta T (2001) Phosphorylated MAP kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11: 144–158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Frame S, Cohen P, Biondi RM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321–1327. [DOI] [PubMed] [Google Scholar]
  • 27. Godemann R, Biernat J, Mandelkow E, Mandelkow EM (1999) Phosphorylation of tau protein by recombinant GSK‐3beta: pronounced phosphorylation at select Ser‐Thr‐Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett 454: 157–164. [DOI] [PubMed] [Google Scholar]
  • 28. Goedert M, Cohen ES, Jakes R, Cohen P (1992) p42 MAP kinase phosphorylation sites in microtubule‐associated protein tau are dephosphorylated by protein phosphatase 2A1. FEBS Lett 312: 95–99. [DOI] [PubMed] [Google Scholar]
  • 29. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P (1997) Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases. FEBS Lett 409: 57–62. [DOI] [PubMed] [Google Scholar]
  • 30. Goedert M, Spillantini MG, Cairns NJ, Crowtler RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8: 159–168. [DOI] [PubMed] [Google Scholar]
  • 31. Goedert M, Spillantini MG, Davis SW (1998) Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Op Neurobiol 8: 619–632. [DOI] [PubMed] [Google Scholar]
  • 32. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Dérijard B, Davis RJ (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15: 2760–2770. [PMC free article] [PubMed] [Google Scholar]
  • 33. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen synthase kinase‐3 induces Alzheimer's disease‐like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147: 58–62. [DOI] [PubMed] [Google Scholar]
  • 34. Hugon J, Terro F, Esclaire F, Yardin C (2000) Markers of apoptosis and models of programmed cell death in Alzheimer's disease. J Neural Transm 59: 125–131. [DOI] [PubMed] [Google Scholar]
  • 35. Ikeda K, Akiyama H, Kiondo H, Haga C (1995) A study of dementia with argyrophilic grains. Possible cytoskeletal abnormality in dendrospinal portion of neurons and oligodendroglia. Acta Neuropathol 89: 409–414. [DOI] [PubMed] [Google Scholar]
  • 36. Illenberger S, Zheng‐Fischhofer Q, Preuss U, Stamer K, Bauman K, Trinczek B, Biernat J, Godemann R, Mandelkow EM, Mandelkow E (1998) The endogenous and cell cycle‐dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 9: 1495–1512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Ip YT, Davis RJ (1998) Signal transduction by the c‐Jun‐N‐terminal kinase (JNK): from inflammation to development. Curr Op Cell Biol 10: 205–219. [DOI] [PubMed] [Google Scholar]
  • 38. Jellinger KA (1998) Dementia with argyrophilic grains (argyrophilic grain dementia) Brain Pathol 8: 377–386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Jellinger KA, Stadelmann C (2000) Mechanisms of cell death in neurodegenerative disorders. J Neural Transm 59: 95–114. [DOI] [PubMed] [Google Scholar]
  • 40. Jenkins SM, Zinnerman M, Graner C, Johnson GV (2000) Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 345: 263–270. [PMC free article] [PubMed] [Google Scholar]
  • 41. Komori T (1999) Tau‐positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9: 663–679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Knowles RB, Chin J, Ruff CT, Hyman BT (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: Implications for MAP kinase activation in Alzheimer disease. J Neuropathol Exp Neurol 58: 1090–1098. [DOI] [PubMed] [Google Scholar]
  • 43. Ledesma MD, Correas I, Avila J, Diaz‐Nido J (1992) Implication of cdc2 and MAP2 kinases in the phosphorylation of tau proteins in Alzheimer's disease. FEBS Lett 308: 218–224. [DOI] [PubMed] [Google Scholar]
  • 44. Lee VMY, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121–1159. [DOI] [PubMed] [Google Scholar]
  • 45. Lin A, Minden A, Martinetto H, Claret FX, Lange‐Carter C, Mercurio F, Johnson GL, Karin M (1995) Identification of a dual specificity kinase that activates the Jun kinase and p38‐Mpk2. Science 268: 289–290. [DOI] [PubMed] [Google Scholar]
  • 46. Lovestone S, Reynolds CH (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309–324. [DOI] [PubMed] [Google Scholar]
  • 47. Lucas JJ, Hernandez F, Gomez‐Ramos P, Morán MA, Hen R, Avila J (2001) Decreased nuclear beta‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3b conditional transgenic mice. EMBO J 20: 27–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Mandelkow EM, Drewes G, Biernati J, Gustke N, Van Lint J, Vandenheede JR, Mandelkow E (1992) Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau. FEBS Lett 314: 315–321. [DOI] [PubMed] [Google Scholar]
  • 49. Martinez‐Lage P, Muñoz DG (1997) Prevalence of diseases associated with argyrophilic grains of Braak. J Neuropathol Exp Neurol 56: 157–164. [DOI] [PubMed] [Google Scholar]
  • 50. Mielke K, Herdegen T (2000) JNK and p38 stress kinases: degenerative effectors of signal‐transduction cascades in the nervous system. Progr Neurobiol 61: 45–60. [DOI] [PubMed] [Google Scholar]
  • 51. Minden A, Karin M (1997) Regulation and function of the JNK subgroup of MAP kinases. Biochem Biophys Acta 133: F85–F104. [DOI] [PubMed] [Google Scholar]
  • 52. Pei JJ, Braak E, Braak H, Grundke‐Iqbal I, Iqbal K, Win‐blad B, Cowburn RF (1999) Distribution of glycogen synthase kinase 3 beta (GSK‐3b) for Alzheimer disease neurofibrillary tangle. J Neuropathol Exp Neurol 58: 1010–1119. [DOI] [PubMed] [Google Scholar]
  • 53. Pei JJ, Grundke‐Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF (1998) Accumulation of cyclin‐dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 29: 267–277. [DOI] [PubMed] [Google Scholar]
  • 54. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AL, Holbrook N, Siedlak SL, Harris PLR, Smith MA (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal tau phosphorylation. NeuroReport 10: 2411–2415. [DOI] [PubMed] [Google Scholar]
  • 55. Raingeaud J, Whitmarsh AJ, Barrett T, Dérijard B, Davis RL (1996) MKK3‐ and MKK6‐regulated gene expression is mediated by the p38 mitogen‐activated protein kinase signal transduction pathway. Mol Cell Biol 16: 1247–1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen‐activated protein kinases ERK2, c‐Jun N‐terminal kinase and p38, and glycogen syn‐thase kinase‐3b. J Neurochem 74: 1587–1595. [DOI] [PubMed] [Google Scholar]
  • 57. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderson BH (1997) Reactivating kinase/p38 phosphorylates protein t in vitro. J Neurochem 69: 191–198. [DOI] [PubMed] [Google Scholar]
  • 58. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH (1997) Stress‐activated/c‐Jun‐N‐terminal kinase phosphorylates t protein. J Neurochem 68: 1736–1744. [DOI] [PubMed] [Google Scholar]
  • 59. Robinson MJ, Cobb MH (1997) Mitogen‐activated protein kinase pathways. Curr Op Cell Biol 9: 180–186. [DOI] [PubMed] [Google Scholar]
  • 60. Rostas JAP, Dunkley PR (1992) Multiple forms and distribution of calcium/calmodulin stimulated protein kinase II in brain. J Neurochem 59: 1191–1202. [DOI] [PubMed] [Google Scholar]
  • 61. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubule (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38: 3549–3558. [DOI] [PubMed] [Google Scholar]
  • 62. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL (2000) casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 21: 503–510. [DOI] [PubMed] [Google Scholar]
  • 63. Sengupta A, Kabat J, Novak M, Wu Q, Grudke Iqbal I, Iqbal K (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys 357: 299–309. [DOI] [PubMed] [Google Scholar]
  • 64. Sengupta A, Wu Q, Grundke‐Iqbal I, Iqbal K, Singh TJ (1997) Potentiation of GSK‐3‐catalyzed Alzheimer‐like phosphorylation of human tau by cdk5. Mol Cell Biochem 167: 99–105. [DOI] [PubMed] [Google Scholar]
  • 65. Sergeant N, David JP, Goedert M, Jakes R, Vermersch P, Buée L, Lefranc D, Wattez A, Delacourte A (1997) Twodimensional characterization of paired helical filamenttau from Alzheimer's disease: demonstration of an additional 74 kDa component and age‐related biochemical modifications. J Neurochem 69: 834–844. [DOI] [PubMed] [Google Scholar]
  • 66. Sergeant N, Wattez A, Delacourte A (1999) Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J Neurochem 72: 1243–1249. [DOI] [PubMed] [Google Scholar]
  • 67. Shaw M, Cohen P (1999) Role of protein kinase B and MAP kinase cascade in mediating the EGF‐dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett 461: 120–124. [DOI] [PubMed] [Google Scholar]
  • 68. Singh TJ, Grundke Iqbal I, Iqbal K (1996) Differential phosphorylation of human tau isoforms containing three repeats by several protein kinases. Arch Biochem Biophys 328: 43–50. [DOI] [PubMed] [Google Scholar]
  • 69. Singh TJ, Grundke Iqbal I, Wu WQ, Chauhan V, Novak M, Kontzekova E, Iqbal K (1997) Protein kinase C and calcium/calmodulin‐dependent protein kinase II phosphory‐late three‐repeat and four‐repeat tau isoforms at different rates. Mol Cell Biochem 168: 141–148. [DOI] [PubMed] [Google Scholar]
  • 70. Singh TJ, Haque N, Grundke Iqbal I, Iqbal K (1995a) Rapid Alzheimer‐like phosphorylation of tau by the synergestic actions of non‐proline‐dependent protein kinases and GSK‐3. FEBS Lett 358: 267–272. [DOI] [PubMed] [Google Scholar]
  • 71. Singh TJ, Zaidi T, Grundke‐Iqbal I, Iqbal K (1995b) Modulation of GSK‐3‐catalyzed phosphorylation of microtubule‐associated protein tau by non‐proline‐dependent protein kinases. FEBS Lett 358: 4–8. [DOI] [PubMed] [Google Scholar]
  • 72. Soderling TR (1999) The Ca2?dependent protein kinase cascade. Trends Neurobiol 10: 375–380. [DOI] [PubMed] [Google Scholar]
  • 73. Sperber BR, Leight S, Goedert M, Lee VM (1995) Glycogen synthase kinase‐3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197: 149–153. [DOI] [PubMed] [Google Scholar]
  • 74. Spittaels K, van den Haute C, Van Dorpe J, Geerts H, Mercken M, Sciot R, Van Lammel A, Loos R, Van Leuven F (2000) Glycogen synthase kinase‐3b phosphorylates protein t and rescues the axonopathy in the central nervous system of human four‐repeat t transgenic mice. J Biol Chem 275: 413440–413449. [DOI] [PubMed] [Google Scholar]
  • 75. Stadelmann C, Bruck W, Bancher C, Jellinger K, Lassmann H (1998) Alzheimer's disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57: 456–464. [DOI] [PubMed] [Google Scholar]
  • 76. Stambolic A, Woodgett JR (1994) Mitogen inactivation of glycogen synthase kinase‐3_ in intact cells via serine9 phosphorylation. Biochem J303: 701–704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Steiner B, Mandelkow EM, Biernat J, Gustke N, Meyer HE, Schmidt B, Mieskes G, Soling HD, Drechsel D, Kirschner MW, Goedert M, Mandelkow E (1990) Phosphorylation of microtubule‐associated protein tau: identification of the site for Ca2?dependent protein kinase II and relationship with tau phosphorylation in Alzheimer tangles. EMBO J 9: 3539–3544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Togo T, Cookson N, Dickson DW (2001) Argyrophilic grain disease: Neuropathology. Frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol 12: 45–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, De Silva R, Lees A, Dickson DW (2002) Argyrophilic grain disease is a sporadic 4‐repeat tauopathy. J Neuropathol Exp Neurol 61: 547–556. [DOI] [PubMed] [Google Scholar]
  • 80. Tolnay M, Clahoun M, Pham HC, Egensperger R, Probst A (1999) Low amyloid (bA) plaque load and relative predominance of diffuse plaques distinguish argyrophylic grain disease from Alzheimer's disease. Neuropathol Appl Neurobiol 25: 295–305. [DOI] [PubMed] [Google Scholar]
  • 81. Tolnay M, Mistl C, Ipsen S, Probst A (1998) Argyrophilic grains of Braak: occurrence in dendrites of neurons containing hyperphosphorylated tau protein. Neuropathol Appl Neurobiol 24: 53–59. [DOI] [PubMed] [Google Scholar]
  • 82. Tolnay M, Monsch AU, Probst A (2001) Argyrophilic grain disease. A frequent dementing disorder in old patients. Adv Exp Med Biol 487: 39–58. [PubMed] [Google Scholar]
  • 83. Tolnay M, Probst A (1998) Ballooned neurons expressing aB‐crystallin as a constant feature of the amygdala in argyrophilic grain disease. Neurosci Lett 246: 165–168. [DOI] [PubMed] [Google Scholar]
  • 84. Tolnay M, Probst A (1999) Review: tau protein: pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 25:171–187. [DOI] [PubMed] [Google Scholar]
  • 85. Tolnay M, Schwietert M, Monsch AU, Stahelin HB, Langui D, Probst A (1997) Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathol 94: 353–358. [DOI] [PubMed] [Google Scholar]
  • 86. Tolnay M, Sergeant N, Ghestem A, Chalbot S, de Vos RAI, Jansen Steur ENH, Probst A, Delacourte A (2002) Argyrophylic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol 104:425–434. [DOI] [PubMed] [Google Scholar]
  • 87. Tolnay M, Spillantini MG, Goedert M, Ulrich J, Langui D, Probst A (1997) Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons. Acta Neuropathol 93: 477–484. [DOI] [PubMed] [Google Scholar]
  • 88. Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, Miller CC, Bayley PM, Anderton BH (1997) Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self‐assembly. Biochem J 323: 741–747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Veeranna GJ, Amin ND, Ahn NG, Jaffe J, Winters CA, Grant P, Pant HC (1998) Mitogen‐activated protein kinases (Erk1, 2) phosphorylate Lys‐Ser‐Pro (KSP) repeats in neurofilament proteins NF‐H and NF‐M. J Neurosci 18: 4008–4021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Whitmarsh AJ, Davis RJ (1996) Transcription factor AP‐1 regulation by mitogen‐activated protein kinase signal transduction pathways. J Mol Med 74: 589–607. [DOI] [PubMed] [Google Scholar]
  • 91. Xiao J, Perry G, Troncoso J, Monteriro MJ (1996) Calcium‐calmodulin‐dependent kinase II is associated with paired helical filaments of Alzheimer's disease. J Neuropathol Exp Neurol 55: 954–963. [DOI] [PubMed] [Google Scholar]
  • 92. Yamada T, McGeer PL (1990) Oligodendroglial microtubular masses: an abnormality observed in some human neurodegenerative diseases. Neurosci Lett 120: 163–166. [DOI] [PubMed] [Google Scholar]
  • 93. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase‐3beta and cyclin‐dependent kinase 5, a component of TPK II. Acta Neuropathol 92: 232–241. [DOI] [PubMed] [Google Scholar]
  • 94. Zheng‐Fischhöfer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E (1998) Sequential phosphorylation of Tau by glycogen synthase kinase 3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer‐specific epitope of antibody AT100 and requires a paired‐helical‐filament‐like conformation. Eur J Biochem 252: 542–552. [DOI] [PubMed] [Google Scholar]
  • 95. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle‐related events in Alzheimer disease. J Neuropathol Exp Neurol 59: 880–888. [DOI] [PubMed] [Google Scholar]
  • 96. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and re‐distribution of c‐Jun N‐terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76: 435–441. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES